Stanley Laman Group Ltd. Takes $3.68 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Stanley Laman Group Ltd. bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 59,404 shares of the medical equipment provider’s stock, valued at approximately $3,683,000. Stanley Laman Group Ltd. owned 0.09% of Lantheus as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC grew its stake in shares of Lantheus by 198.2% in the 3rd quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock worth $149,110,000 after purchasing an additional 1,426,465 shares during the last quarter. Reinhart Partners LLC. increased its holdings in shares of Lantheus by 50.4% in the fourth quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock valued at $84,089,000 after buying an additional 454,753 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Lantheus by 41.9% during the 3rd quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock valued at $90,387,000 after acquiring an additional 384,093 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Lantheus by 12.5% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,294,391 shares of the medical equipment provider’s stock worth $89,934,000 after acquiring an additional 143,794 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Lantheus by 1.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 832,367 shares of the medical equipment provider’s stock worth $57,833,000 after acquiring an additional 15,004 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders have sold a total of 94,545 shares of company stock worth $6,169,936 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Down 0.0 %

LNTH traded down $0.01 on Thursday, reaching $65.20. 602,999 shares of the company traded hands, compared to its average volume of 1,036,479. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $100.85. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. The company has a market cap of $4.47 billion, a price-to-earnings ratio of 14.05 and a beta of 0.53. The stock’s 50 day moving average price is $61.31 and its 200-day moving average price is $62.75.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Truist Financial reissued a “buy” rating and issued a $82.00 target price (up from $80.00) on shares of Lantheus in a research report on Monday, February 26th. JMP Securities restated a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Finally, B. Riley raised their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $104.71.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.